OneSource Specialty Pharma Limited, a contract development and manufacturing organization (CDMO) focused on specialty pharmaceuticals, has entered into a partnership with Xbrane Biopharma AB (Nasdaq: XBRANE), a biotechnology company based in Sweden. The agreement covers commercial manufacturing of Xbrane’s biosimilar products.
Xbrane’s portfolio includes biosimilar candidates with reference products that collectively target an estimated EUR 23 billion in annual peak sales. The lead candidate, Ximluci—a ranibizumab biosimilar—has already received market authorization in Europe and is undergoing the approval process in the United States.
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, stated,”The partnership with Xbrane reflects our shared ambition to drive broader access to cutting-edge biologics worldwide. Xbrane’s proven success in biosimilar development, combined with OneSource’s fully integrated biologics platform, creates a strong platform for global impact. We are pleased to support the scale-up of high-quality biosimilars and advance our vision of being a trusted partner to the world’s leading biotech companies.”
Under the agreement, Xbrane will transfer selected products to OneSource’s integrated Drug Substance and Drug Product manufacturing facility located in Bangalore, India. This collaboration is expected to support Xbrane’s global supply chain requirements and enable OneSource to pursue regulatory approvals for its biologics manufacturing capabilities from agencies such as the U.S. FDA and EMA.
Additionally, OneSource has invested in Xbrane’s recent funding round, indicating long-term cooperation between the two companies.
Ahmedabad Plane Crash